(3 references)-
- 抗原 See all SARS-CoV-2 Spike products
- SARS-CoV-2 Spike
- 宿主
- SARS Coronavirus-2 (SARS-CoV-2)
-
资源
- 合成
- 应用范围
- Inhibition Assay (InhA)
- 序列
- DISGINASVV NIQKEIDRLN EVAKNLNESL IDLQEL
- 产品特性
- 2019-nCov-HR2P
- 纯度
- ≥ 95 %
- 组件
- Each vial contains 100 μg of NET peptide.
-
SARS-CoV-2 Spike peptide
适用: SARS Coronavirus-2 (SARS-CoV-2) 宿主: 合成 InhA
SARS-CoV-2 Spike peptide (Cy5)适用: SARS Coronavirus-2 (SARS-CoV-2) 宿主: 合成 InhA
SARS-CoV-2 Spike peptide (Cy5)适用: SARS Coronavirus-2 (SARS-CoV-2) 宿主: 合成 InhA
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 状态
- Powder
- 储存条件
- RT,4 °C,-20 °C
- 储存方法
- Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." in: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." in: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
-
- 抗原
- SARS-CoV-2 Spike
- 别名
- E2 Peptide, E2 glycoprotein precursor Peptide, Surface Glycoprotein Peptide, S Peptide
- 物质类
- Viral Protein
- 分子量
- 4008.50
- 基因ID
- 43740568
- UniProt
- P0DTC2
-
You are here:
